Red Light Holland Announces Dr. Robin Carhart-Harris as Scientific Advisor
Red Light Holland (OTCQB: TRUFF), a producer of functional mushrooms and psilocybin truffles, has appointed renowned psychedelic researcher Dr. Robin Carhart-Harris as Scientific Advisor. Dr. Carhart-Harris will provide strategic guidance on psilocybin research and assist with academic and regulatory collaborations.
The company highlighted several ongoing initiatives, including: partnerships with Dr. David Nutt and Drug Science for microdosing app data analysis, development of natural microdosing capsules with CCREST Labs, collaboration with Irvine Labs for shelf-life studies, distribution agreement with Allu Therapeutics for Australia/New Zealand markets, and an upcoming research collaboration with Arizona State University for psychedelic genome research.
Red Light Holland (OTCQB: TRUFF), produttore di funghi funzionali e tartufi di psilocibina, ha nominato il rinomato ricercatore psichedelico Dr. Robin Carhart-Harris come Consulente Scientifico. Il Dr. Carhart-Harris fornirà orientamenti strategici sulla ricerca sulla psilocibina e supporterà le collaborazioni accademiche e regolatorie.
L'azienda ha evidenziato diverse iniziative in corso, tra cui: partnership con Dr. David Nutt e Drug Science per l'analisi dei dati di un'app di microdosaggio, sviluppo di capsule naturali per microdosaggio con CCREST Labs, collaborazione con Irvine Labs per studi sulla durata di conservazione, accordo di distribuzione con Allu Therapeutics per i mercati di Australia e Nuova Zelanda, e una prossima collaborazione di ricerca con Arizona State University per lo studio del genoma psichedelico.
Red Light Holland (OTCQB: TRUFF), productor de hongos funcionales y trufas de psilocibina, ha nombrado al reconocido investigador psicodélico Dr. Robin Carhart-Harris como Asesor Científico. El Dr. Carhart-Harris brindará orientación estratégica sobre la investigación de la psilocibina y ayudará en colaboraciones académicas y regulatorias.
La compañía destacó varias iniciativas en curso, incluyendo: asociaciones con Dr. David Nutt y Drug Science para el análisis de datos de una app de microdosificación, desarrollo de cápsulas naturales para microdosificación con CCREST Labs, colaboración con Irvine Labs para estudios de vida útil, acuerdo de distribución con Allu Therapeutics para los mercados de Australia y Nueva Zelanda, y una próxima colaboración de investigación con Arizona State University para estudiar el genoma psicodélico.
Red Light Holland (OTCQB: TRUFF)는 기능성 버섯과 실로시빈 트러플을 생산하는 회사로, 저명한 사이키델릭 연구자 Dr. Robin Carhart-Harris를 과학 고문으로 임명했습니다. Carhart-Harris 박사는 실로시빈 연구에 대한 전략적 조언을 제공하고 학술 및 규제 협력을 지원할 예정입니다.
회사는 다음과 같은 여러 진행 중인 프로젝트를 강조했습니다: 마이크로도징 앱 데이터 분석을 위한 Dr. David Nutt 및 Drug Science와의 파트너십, CCREST Labs와 함께 천연 마이크로도징 캡슐 개발, Irvine Labs와의 유통기한 연구 협력, 호주/뉴질랜드 시장을 위한 Allu Therapeutics와의 유통 계약, 그리고 사이키델릭 유전체 연구를 위한 Arizona State University와의 향후 연구 협력입니다.
Red Light Holland (OTCQB : TRUFF), producteur de champignons fonctionnels et de truffes de psilocybine, a nommé le célèbre chercheur en psychédéliques Dr. Robin Carhart-Harris comme conseiller scientifique. Le Dr Carhart-Harris apportera des conseils stratégiques sur la recherche en psilocybine et aidera aux collaborations académiques et réglementaires.
L'entreprise a mis en avant plusieurs initiatives en cours, notamment : des partenariats avec Dr. David Nutt et Drug Science pour l'analyse des données d'une application de microdosage, le développement de capsules naturelles de microdosage avec CCREST Labs, une collaboration avec Irvine Labs pour des études sur la durée de conservation, un accord de distribution avec Allu Therapeutics pour les marchés australien et néo-zélandais, ainsi qu'une prochaine collaboration de recherche avec Arizona State University pour la recherche sur le génome psychédélique.
Red Light Holland (OTCQB: TRUFF), ein Produzent von funktionellen Pilzen und Psilocybin-Trüffeln, hat den renommierten Psychedelik-Forscher Dr. Robin Carhart-Harris als Wissenschaftlichen Berater ernannt. Dr. Carhart-Harris wird strategische Beratung zur Psilocybin-Forschung bieten und bei akademischen sowie regulatorischen Kooperationen unterstützen.
Das Unternehmen hob mehrere laufende Initiativen hervor, darunter: Partnerschaften mit Dr. David Nutt und Drug Science zur Analyse von Microdosing-App-Daten, Entwicklung natürlicher Microdosing-Kapseln mit CCREST Labs, Zusammenarbeit mit Irvine Labs für Haltbarkeitsstudien, Vertriebsvereinbarung mit Allu Therapeutics für die Märkte Australien/Neuseeland sowie eine bevorstehende Forschungskooperation mit der Arizona State University zur psychedelischen Genomforschung.
- Strategic appointment of leading psychedelic researcher Dr. Robin Carhart-Harris as Scientific Advisor
- Multiple established research partnerships with prestigious institutions and laboratories
- Geographic expansion through distribution agreement for Australia and New Zealand markets
- Four separate Health Canada approved psilocybin import permits obtained
- None.
Toronto, Ontario--(Newsfile Corp. - July 2, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce that Dr. Robin Carhart-Harris, a leading authority in psychedelic research, has joined the Company as an independent Scientific Advisor.
Dr. Carhart-Harris will provide strategic guidance on psilocybin research developments and assist with potential academic and regulatory collaborations. The advisory role will also include regular science-focused discussions to help advance the Company's research initiatives and educational outreach efforts with the aim of increasing safety and responsible access, if and when regulations permit.
"Dr. Robin Carhart-Harris is a true pioneer in psychedelic research, and his groundbreaking work has helped shape the global conversation around mental health innovation," said Todd Shapiro, CEO and Director of Red Light Holland. "Having him join as a Scientific Advisor is not only an honour, it reinforces our dedication to advancing safe, effective, and evidence-based psychedelic solutions through world-class scientific leadership."
The appointment of Dr. Carhart-Harris represents another significant step in Red Light Holland's expanding scientific and market entry strategy, which includes:
- A successful partnership with Dr. David Nutt and Drug Science, analyzing consensual data from the Company's microdosing app in the Netherlands.
- Development of accurately dosed natural microdosing capsules with CCREST Labs in Montreal, Canada via 4 separate Health Canada approved psilocybin import permits of the Company's naturally-occurring psilocybin.
- Collaborating with FDA-compliant and DEA-registered Irvine Labs in California, which has recently received a United States Controlled Substances Import Permit for the Company's naturally-occurring psilocybin and will be working toward increasing the shelf life of the microdosing capsules.
- Distribution agreement with Allu Therapeutics, a specialized entity spun out from NUBU Pharmaceuticals in June 2024, focused solely on distribution and sales of psychedelic products in Australia and New Zealand. Notably, New Zealand has recently allowed for a first prescriber of psilocybin outside of a research setting.
- An upcoming collaboration with Arizona State University to support groundbreaking psychedelic genome project (PGP) research study.
As global markets continue to open up for therapeutic psychedelics, including some very recent positive news in the United States, New Zealand and Czech Republic, Red Light Holland continues to strategically position itself to leverage both their valuable real-world data collected from its operations and insights gained through strategic partnerships to maintain its responsible use policy and support evidence-based approaches to psychedelic medicine.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.
The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's ability to successfully collaborate with Dr. Carhart-Harris; the Company's expectations regarding the benefits of the advisory relationship; statements regarding the potential outcomes of scientific guidance and research support; the Company's ability to effectively leverage the advisory relationship for R&D advancement; the Company's ability to collaborating with FDA-compliant and DEA-registered Irvine Labs in California; the Company's ability to ship their products from the Netherlands to the United States via an United States Controlled Substances Import Permit for the Company's naturally-occurring psilocybin; the Company's ability to then be working toward increasing the shelf life of the microdosing capsules; the companies expectations regarding academic and regulatory collaboration opportunities; the potential impact of the advisory relationship on the Company's research initiatives; statements regarding the Company's position in the psychedelic medicine landscape; the Company's performance, business objectives and milestones and the anticipated timing thereof; the potential benefits resulting from the entering of the distribution agreement between the Company and Allu Therapeutics, including the potential legal import and distribution to New Zealand and Australia and eventually Australasia; the Company's ability to ensure the partnership with with Arizona State University to support groundbreaking psychedelic genome project (PGP) research study creates results needed, the Company and the Company's partners' ability to maintain stated licences and obtain all necessary additional licences and regulatory approval required for the Company to carry out its plans as described; the Company's continued commitment to its products for microdosing that can potentially be accessible in emerging legal markets worldwide.
Forward-looking information in this press release are based on certain assumptions and expected future events, namely: the continued advisory relationship with Dr. Carhart-Harris; the Company's ability to successfully benefit from scientific guidance; the continued operation of laboratory partnerships with Irvine Labs and CCrest Labs; the ability to maintain regulatory compliance throughout collaborative efforts; the successful advancement of R&D initiatives; the continued development of the psychedelic medicine landscape; the Company's ability to maintain or exceed its current performance and carry out its business objectives; the Company's ability to capitalize on the potential benefits resulting from the distribution agreement with Allu Therapeutics; the Company and its partners' abilities to maintain stated licenses and obtain all necessary additional licenses and regulatory approval; the Company's ability to continue developing its products for microdosing that can potentially be accessible in emerging legal markets worldwide.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the inability of the Company to successfully collaborate with Dr. Carhart-Harris; potential changes in the advisory relationship; the inability to effectively leverage scientific guidance for business advancement; potential changes in regulations affecting psychedelic research or the Company's operations; the inability to maintain effective laboratory partnerships; the Company's inability to collaborate with FDA-compliant and DEA-registered Irvine Labs in California; the Company's inability to ship their products from the Netherlands to the United States via an United States Controlled Substances Import Permit for the Company's naturally-occurring psilocybin; the Company's inability to then be working toward increasing the shelf life of the microdosing capsules; the Company's potential challenges in R&D advancement; the Company's inability to maintain or exceed its current performance; the Company's inability to capitalize on the potential benefits resulting from the distribution agreement with Allu Therapeutics; the inability of the Company to complete Arizona State University research study to support groundbreaking psychedelic genome project (PGP); the inability to maintain stated licenses and obtain necessary regulatory approvals; the Company's inability to continue developing products for emerging legal markets.
Readers are cautioned that the foregoing list is not exhaustive. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
The Company cannot make medical claims and is purely in a R&D phase with its partners Irvine Labs Inc.
Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257530
FAQ
Who is Dr. Robin Carhart-Harris and what role will he play at Red Light Holland (TRUFF)?
What are the key research partnerships of Red Light Holland (TRUFF)?
What markets does Red Light Holland (TRUFF) operate in?
What regulatory approvals has Red Light Holland (TRUFF) received for psilocybin?
